137 related articles for article (PubMed ID: 3400639)
21. A study of oral adsorbent in chronic renal failure.
Koide K; Sano M; Takeda F; Momose T; Koshikawa S; Akizawa T
Biomater Artif Cells Immobilization Biotechnol; 1991; 19(1):147-66. PubMed ID: 1751665
[TBL] [Abstract][Full Text] [Related]
22. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
[TBL] [Abstract][Full Text] [Related]
23. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats.
Niwa T; Miyazaki T; Hashimoto N; Hayashi H; Ise M; Uehara Y; Maeda K
Am J Nephrol; 1992; 12(4):201-6. PubMed ID: 1481866
[TBL] [Abstract][Full Text] [Related]
24. [Effect of an oral sorbent (AST-120) on the clinical course of uremic peak 2a in chronic renal failure].
Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Ono S
Nihon Jinzo Gakkai Shi; 1987 Aug; 29(8):1003-11. PubMed ID: 3694879
[No Abstract] [Full Text] [Related]
25. Sorbent membrane dialysis in uremia.
Randerson DH; Gurland HJ; Schmidt B; Farrell PC; Hone PW; Stokoe C; Zuber A; Blogg A; Fateh-Moghadam A; Marschner I; Köpcke W
Contrib Nephrol; 1982; 29():53-64. PubMed ID: 7075216
[TBL] [Abstract][Full Text] [Related]
26. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats.
Aoyama I; Shimokata K; Niwa T
Nephron; 2002 Mar; 90(3):297-312. PubMed ID: 11867951
[TBL] [Abstract][Full Text] [Related]
28. Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure.
Owada A; Shiigai T
Am J Nephrol; 1996; 16(2):124-7. PubMed ID: 8919228
[TBL] [Abstract][Full Text] [Related]
29. Timing of initiation of uremia therapy and survival in patients with progressive renal disease.
Ifudu O; Dawood M; Homel P; Friedman EA
Am J Nephrol; 1998; 18(3):193-8. PubMed ID: 9627034
[TBL] [Abstract][Full Text] [Related]
30. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
Akizawa T; Asano Y; Morita S; Wakita T; Onishi Y; Fukuhara S; Gejyo F; Matsuo S; Yorioka N; Kurokawa K;
Am J Kidney Dis; 2009 Sep; 54(3):459-67. PubMed ID: 19615804
[TBL] [Abstract][Full Text] [Related]
31. [Effect of oral-adsorbent (AST-120) in chronic renal failure (CRF) in rats].
Sakai T; Kumano K; Takara S; Kuwao S; Ise M; Sugano M; Uehara Y
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):359-65. PubMed ID: 2747009
[TBL] [Abstract][Full Text] [Related]
32. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
Clin Exp Nephrol; 2018 Apr; 22(2):299-308. PubMed ID: 28741050
[TBL] [Abstract][Full Text] [Related]
34. Oral sorbent AST-120 increases renal NO synthesis in uremic rats.
Tumur Z; Niwa T
J Ren Nutr; 2008 Jan; 18(1):60-4. PubMed ID: 18089446
[TBL] [Abstract][Full Text] [Related]
35. Relationship between insulin resistance and uremic toxins in the gastrointestinal tract.
Okada K; Takahashi Y; Okawa E; Onishi Y; Hagi C; Aoki K; Shibahara H; Higuchi T; Nagura Y; Kanmatsuse K; Takahashi S
Nephron; 2001 Aug; 88(4):384-6. PubMed ID: 11474237
[TBL] [Abstract][Full Text] [Related]
36. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.
Wu IW; Hsu KH; Sun CY; Tsai CJ; Wu MS; Lee CC
Nephrol Dial Transplant; 2014 Sep; 29(9):1719-27. PubMed ID: 24714415
[TBL] [Abstract][Full Text] [Related]
37. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study.
Owada A; Nakao M; Koike J; Ujiie K; Tomita K; Shiigai T
Kidney Int Suppl; 1997 Dec; 63():S188-90. PubMed ID: 9407455
[TBL] [Abstract][Full Text] [Related]
38. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys.
Miyazaki T; Aoyama I; Ise M; Seo H; Niwa T
Nephrol Dial Transplant; 2000 Nov; 15(11):1773-81. PubMed ID: 11071964
[TBL] [Abstract][Full Text] [Related]
39. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects.
Konishi K; Nakano S; Tsuda S; Nakagawa A; Kigoshi T; Koya D
Diabetes Res Clin Pract; 2008 Sep; 81(3):310-5. PubMed ID: 18550198
[TBL] [Abstract][Full Text] [Related]
40. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF.
Sanaka T; Fujimoto K; Niwayama J; Nishimura H; Naito T; Higuchi C; Akizawa T; Koide K; Koshikawa S
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S35-7. PubMed ID: 12612949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
